Table 5.

Changes in obesity parameters after 12 months dapagliflozin treatment

Variable change	Intention-to-treat analysis				Per-protocol analysis
	Dapaglilflozin	Placebo	Differencea	P-value	Dapaglilflozin	Placebo	Differencea	P-value
	(n = 32)	(n = 34)	(95% CI)		(n = 29)	(n = 33)	(95% CI)
Weight (kg)	−4.27 ± 2.50	−0.50 ± 2.19	−3.77 (−4.92 to −2.61)	<0.001	−4.56 ± 2.41	−0.52 ± 2.22	−4.03 (−5.21 to −2.86)	<0.001
BMI (kg/m2)b	−1.53 ± 0.93	−0.17 ± 0.74	−1.35 (−1.77 to −0.94)	<0.001	−1.63 ± 0.91	−0.18 ± 0.75	−1.45 (−1.87 to −1.03)	<0.001
VAT volume (cm3)c	−565.17 ± 691.27	114.22 ± 593.69	−679.4	<0.001	−625.73 ± 701.18	121.36 ± 611.81	−747.09	<0.001
	(n = 31)		(−998.00 to −360.80)		(n = 28)	(n = 32)	(−1086.34 to −407.84)
SCAT volume (cm3)c	−720.84 ± 687.83	−111.08 ± 643.42	−609.76	0.001	−798.07 ± 679.52	−118.74 ± 665.30	−679.33	<0.001
	(n = 31)	(n = 31)	(−948.13 to −271.28)		(n = 28)	(n = 29)	(−1036.47 to −322.19)
VAT/SCAT volume ratioc	(n = 31)	0.02 ± 0.06	−0.03 (−0.06 to 0.00)	0.023	−0.01 ± 0.06	0.021 ± 0.057	−0.04 (−0.07 to −0.01)	0.023
	−0.01 ± 0.06	(n = 31)			(n = 28)	(n = 29)

P-values in bold indicate <0.05.

BMI, body mass index; SCAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.

^aAbsolute mean difference between groups. All values expressed in mean ± SD unless stated.

^bMedian ±IQR.

^cSome scans removed due to artefact making accurate VAT or SCAT measurement not possible—see text for details.